Chen, Ching-TsoChing-TsoChenCHIH-HUNG HSUANN-LII CHENGYU-YUN SHAO2023-01-102023-01-102022-090250-7005https://scholars.lib.ntu.edu.tw/handle/123456789/627073The reimbursement criteria of sorafenib for advanced hepatocellular carcinoma (HCC) were expanded in 2016 by Taiwan's National Health Insurance (NHI) to include patients without macrovascular invasion or extrahepatic spread. This study explored sorafenib treatment outcomes before and after this expansion.enBarcelona Clinic Liver Cancer Stage C; Hepatocellular carcinoma; National Health Insurance; reimbursement criteria; sorafenib; transarterial chemoembolization[SDGs]SDG3Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Studyjournal article10.21873/anticanres.15946360394312-s2.0-85136874736WOS:000848585700011https://scholars.lib.ntu.edu.tw/handle/123456789/623992